East China Pharmaceutical: Application for registration of new indications for IYANSHI S-shaped forehead filling has been accepted.

East China Pharmaceutical announced that its wholly-owned subsidiary Xinkeli Meixue Supply Chain Management Co., Ltd. received a "Notice of Acceptance" issued by the National Medical Products Administration on June 8, 2026. The application for changes in the registration of three types of medical device injection poly caprolactone microspheres facial filler Ellans Yanshi S Type, which was filed on behalf of the company, was accepted. The new indications added in this application are: implantation under the forehead skin or periosteum to improve moderate to severe forehead contour defects.